Promethazine Hydrochloride (Phenergan) Should Not Be Given To Children Under 6: TGA

Australia: The oral antihistamine promethazine hydrochloride, sold as Phenergan and other generic brands, should not be given to children under 6 years of age.

The pharmaceutical company Sanofi-Aventis Healthcare requested the latest updates to advice in the Product Information (PI), Consumer Medicine Information (CMI) and product label for Phenergan, following an internal investigation. This was prompted by a TGA investigation and advice from our Advisory Committee on Medicines.

The PI and CMI documents have been updated to include the risks of psychiatric and central nervous system side effects in children under 6, including hyperactivity, aggression and hallucination. When high doses are given, these children may also experience difficulties in learning and understanding, such as reversible cognitive deficit and intellectual disability.

Phenergan is used to treat a range of conditions including allergies, hayfever and nausea, as well as for short-term sedation.

There are almost 50 other brands of oral promethazine hydrochloride on the Australian market and these sponsors will also be required to update their PI and CMI documents, and product labelling.

Oral promethazine products are currently available as S3 products which can be given to patients over-the-counter on advice from pharmacists.

For more information see Medicines Safety Update: Promethazine hydrochloride (Phenergan) not to be used in children under 6.

Related Posts

  • Pharma
  • February 1, 2025
  • 218 views
Stricter Rules Soon To Curb Pregabalin, Tapentadol Sales Amid Rising Drug Abuse

New Delhi:  Two painkiller medicines are under the scanner of the Union government following reports of drug abuse. Last year, the apex drug regulatory body of India — Central Drugs…

  • Pharma
  • February 1, 2025
  • 133 views
Nonopioid Drug For Acute Pain Wins FDA Approval

Boston:  A long-awaited nonopioid pain drug won approval yesterday from the U.S. Food and Drug Administration (FDA) to treat moderate to severe short-term pain. Suzetrigine, an oral drug marketed by Vertex…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Union Budget 2025 pleased Healthcare Leaders except for a Letdown or two

Union Budget 2025 pleased Healthcare Leaders except for a Letdown or two

Stricter Rules Soon To Curb Pregabalin, Tapentadol Sales Amid Rising Drug Abuse

Stricter Rules Soon To Curb Pregabalin, Tapentadol Sales Amid Rising Drug Abuse

Nonopioid Drug For Acute Pain Wins FDA Approval

Nonopioid Drug For Acute Pain Wins FDA Approval

One Thousand Narcotic Injections Seized From Biker In Palwal

One Thousand Narcotic Injections Seized From Biker In Palwal